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ABSTRACT
Introduction Patients with atrial fibrillation 
experience an irregular heart rate and have an 
increased risk of stroke; prophylactic treatment 
with anticoagulation medication reduces this risk. 
Direct- acting oral anticoagulants (DOACs) have 
been approved providing an alternative to vitamin K 
antagonists such as warfarin. There is interest from 
regulatory bodies on the effectiveness of medications 
in routine clinical practice; however, uncertainty 
remains regarding the suitability of non- interventional 
data for answering questions on drug effectiveness 
and on the most suitable methods to be used. In this 
study, we will use data from Apixaban for Reduction 
in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation (ARISTOTLE)—the pivotal trial for the DOAC 
apixaban—to validate non- interventional methods for 
assessing treatment effectiveness of anticoagulants. 
These methods could then be applied to analyse 
treatment effectiveness in people excluded from or 
under- represented in ARISTOTLE.
Methods and analysis Patient characteristics from 
ARISTOTLE will be used to select a cohort of patients 
with similar baseline characteristics from two UK 
electronic health record (EHR) databases, Clinical 
Practice Research Datalink Gold and Aurum (between 
1 January 2013 and 31 July 2019). Methods such 
as propensity score matching and coarsened exact 
matching will be explored in matching between EHR 
treatment groups to determine the optimal method of 
obtaining a balanced cohort.
Absolute and relative risk of outcomes in the EHR 
trial- analogous cohort will be calculated and compared 
with the ARISTOTLE results; if results are deemed 
compatible the methods used for matching EHR 
treatment groups can then be used to examine drug 
effectiveness over a longer duration of exposure and 
in special patient groups of interest not studied in the 
trial.
Ethics and dissemination The study has been 
approved by the Independent Scientific Advisory 
Committee of the UK Medicines and Healthcare 
Products Regulatory Agency. Results will be 




Atrial fibrillation (AF) is a common cause of 
cardiac arrhythmia with symptoms including 
palpitations, fainting and shortness of breath; 
however, some patients may be asymptomatic. 
The prevalence of AF in the UK is estimated 
to be around 3%,1 increasing from 0.2% in 
Strengths and limitations of this study
 ► Selection of electronic health record patients 
matched to the randomised controlled trial (RCT) 
patients allows assessment of the ability of non- 
interventional methods to detect effectiveness of 
treatments for stroke prevention in atrial fibrillation 
(AF) within an RCT- analogous population.
 ► Combined Clinical Practice Research Datalink 
(CPRD) Gold and Aurum population broadly repre-
sentative of the patients prescribed apixaban and 
warfarin for AF in routine clinical practice in the UK.
 ► Some of the criteria that were assessed for 
ARISTOTLE eligibility may not be well recorded in 
CPRD.
 ► Adherence to medication will need to be assessed 
based on proxy variables (time covered by prescrip-
tion for the direct- acting oral anticoagulants, time in 
therapeutic range based on international normalised 
ratio measurements for warfarin); the different na-
ture of these proxy variables means the adherence 
estimates may not be comparable.
 ► Ascertainment of outcomes via CPRD is based on 
recording as part of routine clinical care rather than 
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people aged 45–54 years to 8.0% in those 75 and older.2 
The lack of organised atrial contraction in AF can lead to 
the formation of thrombi, meaning that patients with AF 
have a fivefold higher risk of stroke which is an important 
cause of morbidity and mortality.3–5
Current UK guidelines recommend use of prophylactic 
treatment with anticoagulation medication to reduce the 
risk of stroke. Warfarin, a vitamin K antagonist (VKA) and 
the previous standard anticoagulant treatment, has many 
treatment and dietary interactions requiring frequent 
monitoring of a patient’s international normalised ratio 
(INR), to maintain anticoagulant activity within a narrow 
range (2.0–3.0). Low levels put the patient at a higher risk 
of stroke while high levels lead to a higher risk of bleeding.6 
In 2011, the first direct- acting oral anticoagulant (DOAC) 
dabigatran was approved for the treatment of AF in the 
European Union (EU); it was anticipated to provide easier 
to manage long- term anticoagulation therapy for patients 
with AF given the complex safety profile of warfarin. ARIS-
TOTLE, a pivotal randomised controlled trial (RCT) 
of the DOAC apixaban, demonstrated superiority over 
warfarin for both prevention of stroke and safety (major 
bleeding) among individuals with AF.7
The generalisability of the ARISTOTLE trial is limited 
by the strict eligibility criteria; evidence on apixaban’s 
treatment effect is therefore lacking for patients who 
would not have met the eligibility criteria such as those 
at increased bleeding risk or with severe comorbid 
conditions. The regulatory environment now demands 
evidence of treatment effectiveness outside the confines 
of randomised trials.8 9 Non- interventional data sources 
have the potential to overcome many of the RCT limita-
tions given that they contain data for a wide spectrum of 
patients treated with the drug in routine care, including 
patients who would have been not eligible for trials. Data 
collected as part of routine patient care such as electronic 
health record (EHR) provide a valuable opportunity to 
obtain evidence on the effectiveness of apixaban in a 
routine care setting. A key problem with using these data 
is that the absence of randomisation leaves them highly 
susceptible to confounding making it difficult to have 
confidence in the results.
To address this lack of confidence, this study will 
apply innovative matching approaches to create a trial- 
analogous non- interventional cohort for analysis. Records 
from UK EHRs will be matched to ARISTOTLE patients 
before using methods for matching between treatment 
groups within the non- interventional EHR data, creating 
an EHR population similar to the trial population that is 
well balanced by treatment group. If successful, estimates 
of effectiveness and safety of apixaban obtained from 
analysis of this ARISTOTLE- analogous cohort should be 
comparable with the results from the ARISTOTLE trial. 
The non- interventional analysis methods used to obtain 
these results may then be used to reliably estimate effects 
in understudied AF patient groups.
AIMS AND OBJECTIVES
The aims of this study are (1) to measure the association 
between anticoagulation treatments for stroke preven-
tion in AF and time to stroke, systemic embolism (SE), 
myocardial infarction (MI), major bleeding and mortality 
among an ARISTOTLE- analogous cohort of patients 
from UK EHRs, and (2) to develop a methodological 
framework with in- built validation for using observational 
EHRs to answer questions about DOAC risks and bene-
fits in patients not included or under- represented in the 
RCTs.
The specific objectives are to:
Objective 1. Check comparability of EHR data and 
robustness of methods for measuring stroke prevention 
medication effectiveness in an ARISTOTLE- analogous 
cohort using data from EHR data and by comparing with 
ARISTOTLE results.
Objective 2. Extension of trial findings: measure treat-
ment effects of apixaban in patient groups excluded from 
ARISTOTLE.
Objective 3. Comparative effectiveness: compare treat-
ment effectiveness between multiple individual antico-
agulants (warfarin, apixaban, rivaroxaban, dabigatran) 
in ARISTOTLE- eligible cohorts and in patient groups 
excluded from ARISTOTLE.
METHODS AND ANALYSIS
Figure 1 (figure adapted from a study in real- world 
effects of medications for chronic obstructive pulmonary 
disease10) provides an overview of the study, covering the 
objectives and data sources used, and how RCT data will 
be used in Objective 1 to validate methods for analysing 
effectiveness of treatments for stroke prevention in AF 
in non- interventional data. Should Objective 1 prove 
successful the validated methods will be applied to unan-
swered questions in Objectives 2 and 3.
Study design
We will use a retrospective cohort study design using 
longitudinal data to evaluate the effects of prescribing 
apixaban versus warfarin and then versus other DOACs 
for prevention of stroke and SE in AF on key effectiveness 
and safety outcomes using non- interventional primary 
care data.
Setting/data sources
Patient data used in this study will be obtained from 
several sources: primary care data on UK National 
Health Service (NHS) patients from Clinical Practice 
Research Datalink (CPRD) Gold and Aurum databases, 
additional data on hospital events and mortality on 
UK NHS patients with linked data from the Hospital 
Episodes Statistics (HES) and Office for National Statis-
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ARISTOTLE
ARISTOTLE was a randomised, double- blind trial 
completed in 2011, comparing apixaban with warfarin in 
the prevention of stroke and SE. The trial included 18 201 
patients with AF and at least one additional risk factor for 
stroke. The trial was designed to test for non- inferiority of 
apixaban compared with warfarin, and showed apixaban 
superiority for (1) the primary outcome of stroke or SE 
(HR 0.79, 95% CI 0.66 to 0.95),7 (2) the safety endpoint 
of major bleeding (HR 0.69, 95% CI 0.60 to 0.80), and 
(3) death from any cause (HR 0.89, 95% CI 0.80 to 0.99). 
The ARISTOTLE findings led to the National Institute 
for Health and Care Excellence (NICE) guidelines on 
stroke prophylaxis in patients with AF recommending 
apixaban as a treatment. Baseline patient characteristics 
 
A. Work performed by 
others prior to this study 
AF patients 
B. Work to be performed as part of this study 
Included in ARISTOTLE RCT 
AF patients in CPRD Gold and Aurum 
RCT results 




EHR patients not eligible for 




apixaban vs. dabigatran? 
apixaban vs. rivaroxaban? 
Comparative effectiveness of other 
treatments in EHR patients 
Results validated? 
-> objectives 2 and 3 
Figure 1 Overview of study objectives and sources of data for the real- world effects of medications for stroke prevention 
in AF study. AF, atrial fibrillation; CPRD, Clinical Practice Research Datalink; EHR, electronic health record; RCT, randomised 
controlled trial. (A) Work performed by others prior to this study. ARISTOTLE: RCT that investigated effectiveness and safety 
of apixaban vs warfarin in prevention of stroke and systemic embolism in AF patients. RCTs results inform clinical practice 
despite only a subset (based on trial inclusion and exclusion criteria) of the total population of AF patients being included in the 
RCTs of stroke prophylaxis treatments. (B) Work to be performed as part of this study. (1) Objective 1. A cohort of ARISTOTLE- 
analogous patients will be selected from UK EHRs (CPRD Gold and Aurum), by matching EHR patients prescribed apixaban to 
the apixaban patients included in the trial on baseline characteristics. EHR patients prescribed warfarin will then be matched 
to the trial- analogous EHR apixaban patients. An analysis of the effectiveness of apixaban vs. warfarin on prevention of stroke/
systemic embolism will then be performed on this ARISTOTLE- analogous EHR cohort. If the results obtained are comparableto 
those obtained in ARISTOTLE, this will serve as a validation step, showing that data from the non- interventional CPRD Gold and 
Aurum sources can reliably be used to study stroke prevention treatment effects in AF. (2) Objective 2. The validated analysis 
techniques used for Objective 1 will then be used to study UK EHR patients who would not have been eligible for inclusion in an 
RCT or are under- represented in RCTs due to their age or presence of other comorbidities, for whom the comparative effects of 
anticoagulants in stroke prevention in AF is unclear.(3) Objective 3. The validated analysis techniques used for Objective 1 will 
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from ARISTOTLE will be used in selection of participants 
in Objective 1.
CPRD Gold
CPRD Gold is a database containing anonymised data 
from over 625 primary care practices across the UK 
(approximately 13 million patient records) and is repre-
sentative of the UK population with respect to age, gender 
and ethnicity.11 Gold contains information on clinical 
diagnoses, prescribing, referrals, tests and demographic/
lifestyle factors. General practices must meet prespecified 
standards for research- quality data to contribute data.
CPRD Aurum
CPRD Aurum contains primary care records similar to 
Gold but based on practices using EMIS software, whereas 
Gold has data from practices using Vision software. CPRD 
Aurum contains data on 19 million patients from 738 
practices (10% of English practices) with 7 million active 
patients.12
Selection of participants
Participants will be selected from CPRD Gold and Aurum 
between 1 January 2013 and 31 July 2019. All patients will 
need to have been registered with a practice contributing 
research quality data for at least 6 months. Participant 
selection criteria will then vary by objective as detailed 
below.
Objective 1
An overview of each of the steps for participant selection 
for Objective 1 is provided in figure 2.
Step 1
We will select all (HES and ONS linked) patients in the 
EHR cohort (CPRD Gold and Aurum) who would have 
met the following inclusion criteria for the ARISTOTLE 
study, at least 6 months after patient registration in the 
database on or prior to the index date:
 ► Diagnosis of AF.
 ► Age 18+ years.
 ► One or more stroke risk factors (age 75 years or older; 
prior stroke, transient ischaemic attack or SE; conges-
tive heart failure; diabetes mellitus; hypertension).
In ARISTOTLE, patients randomised to apixaban were 
new users of apixaban while both treatment arms were 
allowed to be previous users of warfarin, with patients 
stratified by prior warfarin/VKA exposure. To mirror 
ARISTOTLE, we will assess trial criteria for apixaban 
Figure 2 Flow chart illustrating the assembly of a matched trial- analogous cohort of EHR patients. AF, atrial fibrillation; CPRD, 
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patients on the date of their first prescription of apixaban 
while allowing patients prescribed warfarin to become 
eligible at any warfarin prescription date during the study 
period; furthermore, we will match ARISTOTLE in the 
proportion of new versus prevalent users in both treat-
ment arms. We will then exclude patients who meet any 
of the following ARISTOTLE study exclusion criteria prior 
to their eligible- for- inclusion date:
 ► AF due to reversible causes.
 ► Mitral stenosis.
 ► Increased bleeding risk.
 ► Conditions other than AF requiring chronic 
anticoagulation.
 ► Persistent, uncontrolled hypertension.
 ► Active infective endocarditis.
 ► Current treatment with aspirin >165 mg/day.
 ► Simultaneous current treatment with both aspirin 
and a thienopyridine.
 ► Conditions likely to interfere with participation in the 
trial or cause death within 1 year.
 ► Recent alcohol or drug abuse, or psychosocial reasons 
making study participation impractical.
 ► Recent ischaemic stroke (within 7 days).
 ► Severe renal insufficiency.
 ► Alanine aminotransferase or aspartate aminotrans-
ferase >2× upper limit of normal (ULN) or total bili-
rubin ≥1.5× ULN.
 ► Platelet count ≤100 x109/L
 ► Haemoglobin <90 g/L.
 ► Pregnancy or breast feeding.
Feasibility counts in Gold found approximately 60% 
of patients with AF prescribed apixaban met the ARIS-
TOTLE trial criteria. Details of the algorithms used in 
applying the trial criteria to the EHR data are given in the 
online supplemental file.
Step 2
We will select a subset of apixaban patients from our EHR 
pool to create a cohort that matches the ARISTOTLE 




 ► Body mass index (BMI).
 ► Systolic blood pressure (SBP).
 ► Congestive heart failure or left ventricular systolic 
dysfunction.
 ► Hypertension requiring treatment.
 ► Diabetes mellitus.
 ► Prior stroke/thromboembolism.
 ► Smoking status.
 ► Alcohol consumption.
 ► Level of renal impairment.
 ► Prior VKA/warfarin exposure.
 ► Labile INR in prior users of warfarin.
 ► Concomitant use of: aspirin, antiplatelet or non- 
steroidal anti- inflammatory drug, lipid- lowering drug 
therapy, or CYP3A4 inhibitor.
This step will generate a group of ARISTOTLE- 
analogous apixaban patients, with similar baseline 
characteristics to ARISTOTLE subjects at the point of 
randomisation (n~9000).
The variables selected are expected to influence the 
likelihood of the outcomes of interest. Exact selection 
of matching variables will depend on the quality and 
completeness of the data available and a balance will 
be struck between matched sample size and balance. 
Different methods to facilitate selection of a matched 
cohort will be explored, such as propensity score matching 
(PSM) and coarsened exact matching (CEM),13 a non- 
parametric method that may give estimates with lower 
variance and bias for a given sample size compared than 
other methods.14
Step 3
The resulting trial matched sample of EHR apixaban 
patients will be matched to the warfarin ARISTOTLE- 
eligible EHR patients (figure 2) using a matching method 
such as PSM or CEM (final method selected based on 
giving optimal sample size vs balance). Risk set sampling 
will be employed in order to ensure similar duration of 
prior VKA/warfarin exposure for the prevalent users in 
the apixaban and warfarin EHR cohorts. The covariates 
for consideration in matching between EHR treatment 
arms or construction of a propensity score (PS) model will 
include the variables listed in step 2 along with additional 
EHR variables such as data source (Gold or Aurum), 
socioeconomic status and comorbidities. Each apixaban 
patient from the ARISTOTLE- eligible EHR patients will 
be matched 1:1 with the warfarin EHR patient with the 
closest match giving a trial- analogous cohort of ~18 000.
Step 4
The absolute rates and HR for the outcomes of interest 
(time to: stroke/SE, MI, major bleeding and mortality) 
will then be calculated. For the primary outcome (time to 
stroke/SE) the EHR results will be validated against the 
ARISTOTLE trial results using the criteria detailed in the 
Statistical Analysis section (Validation of observational 
results against ARISTOTLE data).
Objective 2
We will select patient groups who would not have been 
included in ARISTOTLE (and therefore would not have 
been included in the Objective 1 cohort) or who are 
under- represented in ARISTOTLE. Specifically, this will 
include patient groups such as patients with an AF diag-
nosis in the EHR cohort meeting these additional criteria:
 ► Severe comorbid condition: disease with a likelihood 
of causing death within 1 year or reasons making 
participation unpractical (such as dementia).
When matching the apixaban and warfarin patients within 
the patient groups for this objective, additional baseline vari-
ables will be considered compared with the list specified for 
Objective 1, Step 2; namely the H, A, and B components of 
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function, Stroke, Bleeding history or predisposition, Labile 
INR, Elderly (>65 years), Drugs/alcohol concomitantly) not 
included for Objective 1 matching due to being ARISTOTLE 
exclusion criteria. In these special patient populations the 
same outcomes as Objective 1 will be assessed, with absolute 
and relative rates calculated separately in each special patient 
group.
Objective 3
We will select all patients with AF who have a prescription 
for apixaban, warfarin, rivaroxaban or dabigatran in the 
treatment period (between 1 January 2013 and 31 July 2019). 
The ARISTOTLE trial criteria will be applied, followed 
by matching the warfarin, rivaroxaban and dabigatran 
ARISTOTLE- eligible EHR patients in turn to the trial- eligible 
EHR apixaban patients following the methodology outlined 
in Objective 1, Step 3. This process will result in the creation 
of three trial- eligible EHR cohorts: warfarin users matched to 
apixaban users, rivaroxaban users matched to apixaban users 
and dabigatran users matched to apixaban users. Matched 
cohorts of excluded patient groups will also be constructed 
to enable pairwise comparisons of treatment effects in these 
groups using the method outlined in Objective 2. In all 
cohorts, the same outcomes as Objective 1 will be assessed 
with both absolute and relative treatment effects compared.
Exposures, outcomes and covariates
Exposures
For all objectives, exposures will be determined using CPRD 
Gold and Aurum prescribing records and code lists for anti-
coagulant treatments with no restrictions placed on the dose 
prescribed.
For Objectives 1 and 2, use of apixaban is the primary 
exposure of interest and will be compared with warfarin.
For Objective 3, other stroke prevention treatments for AF 
will also be compared, namely dabigatran and rivaroxaban.
Outcomes
Outcomes to be measured are as follows:
 ► Stroke (ischaemic or haemorrhagic) or SE.
 ► Major bleeding.
 ► MI.
 ► All- cause mortality.
 ► Time to AF treatment change.
Outcomes will be ascertained using a combination of 
CPRD, HES and ONS data.
Covariates
The variables to be considered for matching patients are 




ARISTOTLE included 9120 patients in the apixaban arm, 
therefore it was estimated a minimum of 15 000 EHR apix-
aban patients were needed for matching to be feasible. 
In CPRD Gold, approximately 8400 patients were eligible 
(January 2018). Aurum (June 2019) contained 23 526 
apixaban patients with AF not registered in practices that had 
previously contributed data to Gold. Assuming the propor-
tion of Aurum patients meeting ARISTOTLE eligibility 
criteria would be similar to the proportion in Gold (~60%) 
gave an estimate of 14 115 trial- eligible apixaban patients. 
Combining Gold and Aurum is therefore estimated to give 
>22 000 unique trial- eligible EHR apixaban patients.
Objectives 2 and 3
From feasibility counts, we are confident we will have suffi-
cient numbers of patients to allow well- powered analyses for 
Objectives 2 and 3. For example, we estimate the number of 
people with no evidence of at least one additional risk factor 




ARISTOTLE used an intent- to- treat (ITT) approach 
for the primary efficacy analysis and an on- treatment 
approach for sensitivity analysis and safety outcomes. We 
will perform equivalent analyses by using two different 
censoring schemes: a primary censoring scheme censoring 
5 years after index date (reflecting the maximum possible 
follow- up in ARISTOTLE) for the primary effectiveness 
analyses, and an on- treatment scheme censoring around 
time of last study drug for the sensitivity analysis and safety 
outcome. For the on- treatment censoring scheme, date of 
last exposure will be estimated using patient prescription 
data—to allow for drug half life, stockpiling of tablets and 
less than 100% adherence we will add 30 days after the 
apparent end of treatment.
Demographic and baseline variables will be presented 
before and after matching steps. As the primary analysis 
accounts neither for treatment switching nor discontinu-
ation, the proportion of patients discontinuing treatment 
and time to treatment discontinuation will be tabulated.
The primary effectiveness endpoint is time to first 
occurrence of confirmed stroke (ischaemic, haem-
orrhagic or unspecified type) or SE during the study, 
regardless of whether the subject is receiving treatment at 
the time (primary censoring scheme). Comparisons will 
be made according to prescribed treatment (apixaban vs 
warfarin).
All time to event endpoints will be analysed using a Cox 
proportional hazards model including treatment group 
as a covariate and prior warfarin/VKA status (experi-
enced, naïve). Point estimates and two- sided 95% CIs will 
be constructed for the outcome. Absolute event rates of 
all outcomes of interest will also be calculated.
Secondary outcomes cover the key safety outcome of 
major bleeding and the individual outcomes of stroke, 
SE, MI and mortality. Secondary outcomes other than 
major bleeding will use the ITT censoring scheme, major 
bleeding will use the on- treatment censoring scheme.
Validation of observational results against ARISTOTLE data
In Objective 1 alone, we will validate the findings from 
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whether results are compatible with the trial results. ARIS-
TOTLE demonstrated superiority of apixaban over warfarin 
for the primary endpoint (HR 0.79, 95% CI 0.66 to 0.95).7 
The treatment effect seen with EHR data may be weaker than 
that seen in ARISTOTLE.
An analysis of EU patients in ARISTOTLE showed a 
smaller treatment difference for the primary endpoint and 
death: HR for stroke/SE 0.92 (95% CI 0.56 to 1.52), all- cause 
death 0.89 (95% CI 0.68 to 1.18). The European Medicines 
Agency Assessment Report suggested the smaller treatment 
effect may have been due to superior INR control in the 
warfarin arm of the EU subgroup (median time in thera-
peutic range (TTR) 68.93%)15; this study could provide addi-
tional evidence on this point.
Either a result of superiority or non- inferiority will be 
considered compatible with ARISTOTLE results. We have set 
two criteria that must be met to conclude results are consis-
tent with the trial result:
1. The effect size must be clinically comparable with the 
ARISTOTLE findings; the HR for time to stroke/SE 
with the EHR must be between 0.69 and 0.99. This 
range is not symmetrical around the ARISTOTLE esti-
mate of 0.79 as it is anticipated the treatment effect in 
routine clinical care may be weaker than that seen in 
the optimised setting of a clinical trial.
2. The upper limit of the 95% CI for the rate ratio must 
be less than 1.52 (upper limit in the EU subgroup of 
ARISTOTLE).
In addition, if the upper limit of the 95% CI is less than 
1 then superiority of apixaban versus warfarin will be 
concluded.
In order to understand the extent to which the EHR 
population resembles the ARISTOTLE trial population 
the absolute event rates of the outcomes will be compared.
Sensitivity analyses
Primary and secondary effectiveness outcomes will also 
be analysed using the on- treatment censoring scheme to 
investigate whether the extent of treatment discontinuation 
compromises confidence in the effectiveness analyses.
Exclusion of patient time post- treatment discontinuation 
in the safety and sensitivity analyses might bias results towards 
a conclusion of no difference16 and risks selection bias due to 
attrition17; the set of patients who switch or discontinue treat-
ment will therefore be examined to ascertain whether biases 
of this nature may have occurred.
Additional analyses may be performed using methods 
such as inverse probability of censoring weighting (IPW) or 
a rank- preserving structural failure time model to estimate 
the treatment effect that would have been observed in the 
absence of treatment switching. We will explore the impact of 
time- varying eligibility by using methods such as a modified 
treatment strategy IPW.17
Adherence will be estimated in the EHR cohort to enable 
comparisons with the trial and investigate the extent to which 
this may have influenced differences in treatment effect 
observed. For apixaban, we will calculate the proportion of 
days covered (PDC) over a patient’s time when on treatment 
as a measure of adherence. Warfarin dose is poorly recorded 
in EHR, therefore warfarin adherence will be estimated by 
looking at adherence to other long- term daily medications as 
a proxy measure and by looking at INR control by calculating 
per cent INR TTR as a measure of overall warfarin treatment 
regime adherence.
We will perform a supplementary analysis in patients 
deemed adherent (PDC ≥80% matching ARISTOTLE 
compliance limit) along with an exploratory subgroup anal-
ysis by INR TTR. The different nature of the proxy variables 
used for adherence in the DOACs (PDC) compared with 
warfarin (INR TTR) means that the adherence estimates may 
not be comparable; should great differences in adherence be 
observed between these exposure groups the definitions of 
adherence used may need to be reassessed.
Apixaban was a newly available drug with a low number 
of patients having a prescription in the first year it was avail-
able18; we will therefore perform a sensitivity analysis with the 
start of the study period shifted forwards a year to January 
2014 to investigate the impact of inclusion of early adopters 
who may differ from later adopters of a new drug.
Plan for addressing confounding
In the study period, apixaban was a newly available treatment 
leading to the possibility of channelling bias. For Objective 1, 
by applying trial eligibility criteria to both treatment cohorts 
and matching using the baseline covariates we should avoid 
channelling bias. To handle confounding, treatment arms 
will be matched using the optimal method selected. Unmea-
sured or unknown confounding may remain and this will be 
explored in the analysis and discussion of results.
Missing baseline data
UK EHR data have been shown to be almost complete for 
drug prescribing and information on important comorbidity 
is well recorded. For some variables such as renal function 
and alcohol intake, a patient is more likely to have no data 
entered if there is no overt clinical evidence of abnormality; 
in such cases, we may take a pragmatic approach categorising 
into a parameter (‘evidence of’ vs ‘no evidence of’) with those 
with no data included in the ‘no evidence of’ group. For BMI 
and SBP, we cannot assume data are missing at random as 
we expect a patient is less likely to have these recorded if 
they appear at a healthy weight and do not have hyperten-
sion, respectively, or if they have a lower comorbidity burden. 
Furthermore, as the proportion of patients with missing base-
line BMI or SBP is expected to be low (approximately 4% 
for BMI and <1% for SBP18), these patients will be excluded 
from the trial- eligible cohort.
Missing prescription data
Treatment may be initiated in secondary care, meaning 
the first prescription of patients newly initiating treatment 
or switching treatments is missing; to account for this we 
will perform a sensitivity analysis where those newly initi-
ating treatment are assigned an earlier derived index date. 
Hospitalised patients may have prescriptions in secondary 
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We will investigate the occurrence of hospitalisation around 
treatment discontinuation and assess the potential impact 
on the results of missed events by performing a sensitivity 
analysis with different extended derived dates of last dose. 
Some concomitant drugs used in determining eligibility and 
matching patients are available over the counter (OTC), 
meaning we may miss that patients are exposed to these; we 
expect OTC use of these drugs to be similar in both treat-
ment groups.
Missing outcome data
EHR data are shown to be almost complete for mortality.19 
Patient deaths missing from EHRs are expected to be missing 
at random equally in both treatment arms, thereby not 
altering the overall direction of treatment effect. The classi-
fication of unspecified stroke type will cause uncertainty in 
the main safety endpoint and may lead to a lower event rate 
for major bleeding compared with the trial; this would affect 
the power but should not affect the treatment effect seen as 
events are expected to be missing at random from both treat-
ment arms.
Limitations of the study design, data sources and analytical 
methods
Some of the criteria assessed for ARISTOTLE eligibility may 
not be well recorded in CPRD, criteria such as alcohol and 
drug abuse may not be captured for all patients. For criteria 
such as ‘increased bleeding risk’, it is unclear which codes 
to include and timescale to consider. These limitations are 
consistent with our aim to select a population as similar as 
possible to ARISTOTLE while acknowledging differences 
will remain. The most important risk factors for the primary 
outcome of stroke (the components of CHA2DS2- VASc score 
for AF stroke risk) are mostly well recorded in CPRD.20
There are differences in the coding systems used by the 
two EHR data sources and completeness of coding may 
differ between the two; the potential impact of this will be 
ascertained by comparisons of rates of diagnoses, baseline 
variables and prescriptions of interest. Inclusion of data 
source as a matching variable should prevent discrepancy 
between the sources from biasing results. We will explore 
different methods of combining Gold and Aurum, namely 
analysing separately by database and combining the results 
as a meta- analysis as an alternative to combining data before 
analysis.
The main focus of the study is validation of our method-
ology through assembling a cohort of patients comparable 
to the patients in ARISTOTLE and finding similar results to 
the trial. Criteria to determine the success of the method-
ology have been prespecified in the protocol. Given the use 
of CPRD data to determine treatment effectiveness is not yet 
well established, a finding that these data are not suitable to 
answer questions on intended effectiveness will be a useful 
conclusion.
Patient and public involvement
No patient was involved.
ETHICS AND DISSEMINATION
Approval by ethics and scientific committees
An application for scientific approval related to use of CPRD 
data was approved by the Independent Scientific Advisory 
Committee of the Medicines and Healthcare Products Regu-
latory Agency (MHRA).
Dissemination plans
The results of the study will be submitted to peer- reviewed 
journals and presented at conferences. Relevant charities 
will be contacted for guidance on dissemination of results to 
patients in an accessible manner. We will communicate with 
NICE to convey any results relevant to the guidance they have 
issued on AF, and with the MHRA if findings may impact the 
risk/benefit profile of anticoagulation treatments in patients 
with AF.
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Appendix Table: ARISTOTLE Inclusion and Exclusion Criteria Algorithms for EHR  
To be trial eligible a patient must have all inclusion criteria (IE01 to IE03)=Y and no exclusion (IE05 to IE27c)=Y 
Criteria 
# Used? Criteria Text (from ARISTOTLE protocol) Implementation Rule and Notes 
  Inclusion Critera (IE01 to IE04a)  
IE01 Y Age ≥ 18 years 
Calculate age at index date, day and month of birth not available therefore 
calculate age by assuming birthdate=01-July-birthyear: 
age =(indexdate-birthdate)/365.25 
 
If age ge 18 then IE01=Y. 
IE02 Y 
In atrial fibrillation or atrial flutter not due to a reversible cause and 
documented by ECG at the time of enrollment. OR If not in atrial 
fibrillation/flutter at the time of enrollment, must have atrial 
fibrillation/flutter documented on two separate occasions, not due to a 
reversible cause at least 2 weeks apart in the 12 months prior to enrollment. 
Atrial fibrillation/flutter may be documented by ECG, or as an episode lasting 
at least one minute on a rhythm strip, Holter recording, or intracardiac 
electrogram (from an implanted pacemaker or defibrillator). 
If patient has medical record corresponding to atrial fibrillation or atrial flutter on 
or prior to index date then IE02=Y.  
  One or more of the following risk factor(s) for stroke: IE03=Y if at least one of (IE03a, IE03b, IE03c, IE03d, IE03e) is Y. 
IE03a Y Age 75 years or older 
See IE01 for derivation of age at index date. 
If age ge 75 then IE03a=Y 
IE03b Y Prior stroke, TIA or systemic embolus 
If patient has medical record corresponding to stroke, TIA, or systemic embolus 
diagnosis on or prior to index date then IE03b=Y.  
 
Codelist search terms include 'stroke', 'cerebrovascular accident', 'cerebral 
infarction', 'lacunar',  'transient ischaemic attack', and synonyms for these.  
IE03c Y 
Either symptomatic congestive heart failure within 3 months or left 
ventricular dysfunction with an LV ejection fraction (LVEF) ≤ 40% by 
echocardiography, radionuclide study or contrast angiography 
If patient has medical record corresponding to congestive heart failure or left 
ventricular dysfunction diagnosis on or prior to index date then IE03c=Y. 
 
Codelist search terms include 'heart failure', 'cardiac failure', 'congestive heart 
failure', 'cardiomyopathy', 'left ventricular dysfunction',  'left ventricular', 'lvef', 
'new york heart association classification', 'hypertensive heart', and synonyms for 
these.  
IE03d Y Diabetes mellitus 
If patient has medical record corresponding to diabetes diagnosis on or prior to 
index date then IE03d=Y. 
 
Codelist search terms include ‘diabetes’, both type 1 and type 2 diabetes are 
included. 
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Criteria 
# Used? Criteria Text (from ARISTOTLE protocol) Implementation Rule and Notes 
IE03e Y Hypertension requiring pharmacological treatment 
If patient has medical record corresponding to hypertension on or prior to index 
date AND a prescription for an antihypertensive on or prior to index date then 
IE03e=Y. 
 
Hypertension codelist search terms include 'hyperten',  'high blood pressure',  
‘nephrosclerosis', and synonyms for these.  
IE04 N 
Women of childbearing potential (WOCBP) must be using an adequate 
method of contraception to avoid pregnancy throughout the treatment 
period of the study or for 2 weeks after the last dose of study medication, 
whichever is longer, in such a manner that the risk of pregnancy is 
minimized. WOCBP must have a negative serum or urine pregnancy test 
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 48 hours 
prior to the start of investigational product. 
This criteria is only partially applied - women with evidence of recent pregnancy or 
breastfeeding will be excluded (see IE27c). 
IE04b N All subjects must provide signed written informed consent. N/A for observational study 
  Exclusion criteria (IE05 to IE27d)  
IE05 Y 
Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis, 
pericarditis) 
If patient has medical record corresponding to reversible AF causes on or prior to 
index date then IE05=Y. 
 
Codelist search terms include 'thyrotoxicosis', 'pericarditis', and synonyms for 
these.  
IE06 Y Clinically significant (moderate or severe) mitral stenosis 
If patient has medical record corresponding to mitral stenosis on or prior to index 
date then IE06=Y. 
 
Cannot determine clinical significance of ‘mitral stenosis’ terms in CPRD therefore 
assume if there is a record of mitral stenosis the condition is clinically significant. 
IE07 Y 
Increased bleeding risk that is believed to be a contraindication to oral 
anticoagulation (e.g. previous intracranial hemorrhage) 
If patient has medical record corresponding to increased bleeding risk on or prior to 
index date then IE07=Y. 
 
Codelist search terms include 'haemorrhag', 'bleed', 'aneurysm', (('intracranial' or 
'brain') and ('neoplasm' or 'tumour' or 'cancer')), 'arteriovenous malformation',  
 'immune thrombocytopenic purpura', 'evans disease', 'hemolytic anemia', 
'haemophilia',  'von willebrand disease', ('glanzmann' and 'thrombasthenia'), 
'wiskott–aldrich syndrome', 'thrombocytopenia' and synonyms for these.  
 
For some forms of more common past bleeding event such as bleeding related to 
menstrual or uterine bleeding, bleeding associated with surgery or injury, bleeding 
associated with ulcer or gastritis, eye bleeding (retinal, conjunctival) we apply the 
additional criteria that these must be within the last two years to be included as 
evidence of increased bleeding risk. 
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Criteria 
# Used? Criteria Text (from ARISTOTLE protocol) Implementation Rule and Notes 
IE08 Y 
Conditions other than atrial fibrillation that require chronic anticoagulation 
(e.g. prosthetic mechanical heart valve) 
If patient has medical record corresponding to a condition other than atrial 
fibrillation that requires chronic anticoagulation on or prior to index date then 
IE08=Y. 
 
Codelist search terms include  (('heart' or 'valve') and ('prosth' or 'mechanical')),   
'venous thromb', and synonyms for these. 
IE09 Y 
Persistent, uncontrolled hypertension (systolic BP > 180 mm Hg, or diastolic 
BP > 100 mm Hg) 
If patient has at least 2 blood pressure readings over the limit (systolic BP > 180 mm 
Hg, or diastolic BP > 100 mm Hg) in the 6 months prior to the index date  
OR  
the patient has a medical record (within 180 days prior to index date) indicating 
uncontrolled hypertension then IE09=Y 
 
Codelist search terms include 'poor hypertension control', 'hypertensive crisis', 
'malignant hypertension', 'severe hypertension', 'hypertension resistant to drug 
therapy', and synonyms for these. 
IE10 Y Active infective endocarditis 
If patient has medical record corresponding to endocarditis on or prior to index 
date then IE10=Y. 
IE11 N Planned major surgery N/A – do not look at future events when determining eligibility 
IE12 N Planned atrial fibrillation or flutter ablation procedure N/A – do not look at future events when determining eligibility 
IE13 N Use of an unapproved, investigational drug or device within the past 30 days N/A – not appropriate to apply when looking at observational data 
IE14 Y Required treatment with aspirin > 165 mg/day 
If patient has a prescription for aspirin with dose > 165 mg/day and prescription 
data suggests drug exposure ongoing at index date then IE14=Y. 
Note this will not pick up patients taking regular aspirin over the counter (study 
limitation). 
IE15 Y 
Simultaneous treatment with both aspirin and a thienopyridine (e.g., 
clopidogrel, ticlopidine) 
If both aspirin and thienopyridine ongoing at index date (ie derived exposure covers 
index date) then IE15=Y. 
IE16 Y Severe comorbid condition with life expectancy of ≤ 1 year 
If patient has medical record corresponding to a condition with a low median 
survival time then IE16=Y. 
Codelist search terms include pancreatic, oesophageal, stomach, liver, gallbladder, 
biliary duct, bladder, lung or brain cancer, multiple myeloma, mesothelioma, CJD, 
and synonyms for these.  
IE17 Y 
Active alcohol or drug abuse, or psychosocial reasons that make study 
participation impractical 
If patient has medical record corresponding to drug or alcohol abuse or any 
complications of abuse, conditions involving an impaired mental state (dementia 
including subtypes such as Alzheimer’s), severe mental health conditions 
(schizophrenia, psychosis, bipolar) then IE17=Y. 
IE18 Y Recent ischemic stroke (within 7 days) 
If patient has medical record corresponding to ischemic stroke within 7 days of 
index date (prior) then IE18=Y. 
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Criteria 
# Used? Criteria Text (from ARISTOTLE protocol) Implementation Rule and Notes 
IE19 Y 
Severe renal insufficiency (serum creatinine > 2.5 mg/dL or a calculated 
creatinine clearance < 25 mL/min, See Section 6.3.2.2) 
If patient has lab result showing serum creatinine > 2.5 mg/dL or a calculated 
creatinine clearance < 25 mL/min within 90 days prior to index date 
OR 
a medical record corresponding to severe renal insufficiency (chronic kidney 
disease stage 4 or 5, dialysis) 
then IE19=Y 
IE20 Y 
ALT or AST > 2X ULN or a Total Bilirubin  ≥  1.5X ULN (unless an alternative 
causative factor [e.g., Gilbert’s syndrome] is identified) 
If patient has lab result showing ALT or AST > 2X ULN or a Total Bilirubin  ≥  1.5X 
ULN within 90 days prior to index date (AND no diagnosis of Gilbert’s syndrome) 
then IE20=Y 
IE21 Y Platelet count ≤ 100,000/ mm3 
If patient has lab result showing platelet count ≤ 100,000/ mm3 within 90 days 
prior to index date 
OR 
a medical record of thrombocytopenia within 90 days prior to index date 
then IE21=Y 
IE22 Y Hemoglobin < 9 g/dL 
If patient has lab result showing hemoglobin < 9 g/dL within 90 days prior to index 
date then IE22=Y  
IE23 N Inability to comply with INR monitoring 
Patients unlikely to be able to comply with INR monitoring – evidence of drug or 
alcohol abuse, impaired mental state, severe mental health conditions. All these 
conditions are already excluded by IE17   
IE24 N Prior randomization into an apixaban clinical study N/A  
IE25 N Prisoners or subjects who are involuntarily incarcerated N/A 
IE26 N 
Subjects who are compulsorily detained for treatment of either a psychiatric 
or physical (e.g., infectious disease) illness N/A 
  N 
Women of child bearing potential (WOCBP) unwilling or unable to use an 
acceptable method to avoid pregnancy: 
   
N/A – see IE27c 
IE27a N WOCBP using a prohibited contraceptive method 
N/A 
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IE27b N 
WOCBP include any female who has experienced menarche and who has not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal 
ligation, or bilateral oophorectomy) or is not postmenopausal [defined as 
amenorrhea ≥ 12 consecutive months, or women on hormone replacement 
therapy (HRT) with documented serum follicle stimulating hormone (FSH) 
level > 35 mIU/mL]. Even women who are using oral contraceptives, other 
hormonal contraceptives (vaginal products, skin patches, or implanted or 
injectable products), or mechanical products such as an intrauterine device 
or barrier methods (diaphragm, condoms, spermicides) to prevent 
pregnancy, or are practicing abstinence or where their partner is sterile (e.g., 
vasectomy) should be considered to be of child bearing potential 
N/A 
  
IE27c Y Women who are pregnant or breastfeeding 
Exclude women who have any medical codes relating to pregnancy (regardless of 
the outcome of the pregnancy), childbirth, antenatal or postnatal care, or 
breastfeeding in the 3 years prior to the patient’s index date. 
IE27d N 
Women with a positive pregnancy test on enrollment or prior to 
administration of investigational product. 
  
N/A – covered by IE27c 
 
Note: Algorithms are under development as part of this study and may be further refined prior to being finalised.  
N/A = Not Applicable. For IE19-IE22 involving lab results a pragmatic approach will be taken in which a patient is assumed not to have the exclusion criteria if there is no lab 
result available in the 90 days prior to index date and the latest available lab result prior to index date does not meet the criteria.    
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